JNJ-61610588
Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies
- First Posted Date
- 2020-07-17
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- Curis, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT04475523
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer
- First Posted Date
- 2016-02-02
- Last Posted Date
- 2018-03-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT02671955
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath